<DOC>
	<DOCNO>NCT00378235</DOCNO>
	<brief_summary>IL13-PE38QQR oncology drug product consist IL13 ( interleukin-13 ) PE38QQR ( bacteria toxin ) . IL3-PE38QQR protein exhibit cell kill activity variety IL13-receptor positive tumor cell line indicate may show therapeutic benefit . In reciprocal competition experiment , interaction IL13-PE38QQR IL13 receptor show highly specific human glioma cell .</brief_summary>
	<brief_title>Phase I/II Trial Intracerebral IL13-PE38QQR Infusions Pediatric Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>PHASE I OBJECTIVES : I . To describe toxicity estimate maximum safe flow rate maximum tolerate infusion concentration , IL13-PE38QQR deliver surgical resection peritumoral infusion via 2 4 catheter position brain adjacent resection cavity , start infusion DLT observation period . II . To determine IL13 receptor alpha-2 chain expression status distribution pediatric recurrent progressive malignant glioma . III . To describe overall safety tolerability IL13PE38QQR infusion start infusion disease progression initiation alternative treatment . PHASE II OBJECTIVES : I . To estimate survival distribution post initial progression , maximum safe total flow rate MTiC establish phase I. II . To estimate progression-free survival distribution patient post-initial progression recurrence maximum safe total flow rate MTiC establish phase I. III . To determine serum level IL13-PE38QQR distribution pediatric recurrent progressive malignant glioma . IV . To describe overall safety tolerability IL13-PE38QQR infusion start infusion disease progression initiation alternative treatment . PROTOCOL OUTLINE : At study entry , patient register prior plan gross total resection ( &gt; 95 % resection solid , contrast enhance tumor component ) . On day catheter placement ( CP , 2-7 day resection ) , patient neurologically stable , 2-4 catheter stereotactically place . On day 1 catheter placement , infusion IL3-PE38QQR begin patient neurologically stable continue 96 hour . In Phase I , total flow rate concentration IL3-PE38QQR determine dose escalation plan . In Phase II evaluation safety efficacy , patient treat flow rate concentration identify Phase I . PROJECTED ACCRUAL : Approximately 24 patient participate Phase I portion study . During Phase I portion , rate-limiting factor time study must close toxicity assessment period . Although estimate 1.5 patient per month enroll Phase I portion , observed rate may lower due temporary suspension accrual . It possible estimate time required complete Phase I portion trial . It estimate approximately 26 patient contribute Phase II portion . Using rough estimate accrual , Phase II portion may last 3 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>Disease Characteristics Must least 3 year 21 year age . Must surgery ( biopsy ) supratentorial brain tumor pathologic diagnosis malignant ( grade 3 4 ) glioma , include anaplastic astrocytoma , mixed anaplastic astrocytoma , glioblastoma multiforme . Must radiographic evidence recurrent progressive supratentorial malignant glioma compare prior image study . The baseline tumor measurement must determine within 2 week prior study entry . The tumor must solid component least 1.0 cm diameter . Gross total resection must plan , intent remove contrastenhancing component tumor . Must receive external beam radiotherapy , tumor dose least 48 Gy ; must complete least 8 week prior study entry . Patient Characteristics Karnofsky Performance Score patient older 16 year , Lansky Performance Scale patient 16 year old young , must least 60 . Hematologic status : Absolute neutrophils least 1,500/mm3 ; Hemoglobin least 10 gm/dL ( transfusion independent ) ; Platelets least 100,000/mm3 ( transfusion independent ) ; PT &amp; aPTT less equal institutional upper limit normal . Must recover toxicity prior therapy : least 6 month Gliadel® wafer ; least 8 week hematopoietic stem cell transplant ; least 4 week cytotoxic chemotherapy systemic investigational agent ; least 6 week nitrosoureas ; least 2 week vincristine noncytotoxic chemotherapy . Patient 's legal guardian must understand investigational nature study potential risk benefit ; must sign informed consent . No pregnant breastfeeding patient . All patient childbearing age , male female , must practice effective method birth control study . No patient multifocal tumor amenable gross total resection tumor dissemination ( subependymal leptomeningeal ) . No patient clinically significant increase intracranial pressure ( e.g. , impending herniation ) uncontrolled seizure , requirement immediate palliative treatment . No patient receive localized antitumor therapy malignant glioma , either intracerebral chemotherapy ( Gliadel® ) focal radiation therapy ( e.g. , stereotactic radiosurgery brachytherapy ) . No patient receive concurrent chemotherapy ( steroid ) investigational agent . No patient unwilling follow protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>neurosurgery , craniotomy</keyword>
	<keyword>convection-enhanced delivery</keyword>
	<keyword>CNS interstitial infusion</keyword>
	<keyword>recombinant toxin</keyword>
	<keyword>malignant glioma , recurrent</keyword>
	<keyword>catheter ,</keyword>
	<keyword>intratumoral therapy</keyword>
	<keyword>positive pressure microinfusion</keyword>
</DOC>